A Harvard-trained physician with a unique perspective is challenging everything mainstream medicine teaches about cholesterol and heart disease.
Dr. Nick Norwitz has cholesterol levels that sometimes exceed 700—numbers that would terrify most cardiologists.
Yet his heart and blood vessels remain pristine, defying conventional medical wisdom about lipids and cardiovascular risk.
His personal health paradox led him down a research rabbit hole that uncovered a largely ignored protein that may hold the real key to longevity and heart health.
The “Lower Is Better” Fallacy Doesn’t Hold Up
For decades, cardiology has operated on a simple principle: lower LDL cholesterol and apolipoprotein B (ApoB), and you’ll live longer.
But Dr. Norwitz points to compelling genetic evidence that challenges this assumption. Take mutations in the PCSK9 gene, which dramatically lower LDL cholesterol and ApoB levels—yet provide no lifespan benefit whatsoever.
How could heart disease be a leading killer, but genetics that should and often do reduce LDL and heart disease risk don’t provide any lifespan benefit?
Even stranger, PCSK9 loss-of-function mutations trend toward earlier death rather than longevity, though the findings aren’t statistically significant.
If simply having lower LDL were the answer, we’d expect at least some survival advantage. We don’t see that.
Meet ApoC3: The Cholesterol Player You’ve Never Heard Of
While medicine obsesses over ApoB, Dr. Norwitz argues we’re missing something critical: apolipoprotein C3 (ApoC3).
ApoC3 is a small protein manufactured in the liver that plays an outsized role in how your body processes fats, particularly triglycerides.
Think of ApoC3 as a metabolic brake pedal. When active, it prevents an enzyme called lipoprotein lipase from breaking down triglycerides, causing these fats to circulate longer than they should.
Here’s where it gets fascinating: people with genetic mutations that reduce or disable ApoC3 demonstrate superior metabolic health, lower cardiovascular risk, and significantly longer lifespans.
Centenarians Are 2.5 Times More Likely to Carry This Genetic Variant
Research examining genetic variations linked to longevity uncovered something remarkable about ApoC3.
Centenarians—people who live past 100—were 2.5 times more likely to carry specific genetic variants that reduce ApoC3 levels compared to those who died younger.
But here’s the kicker: LDL cholesterol and ApoB levels were virtually identical between those with the longevity variant and comparison groups.
In fact, if anything, ApoB levels were trending towards slightly higher levels in at least males with the longevity ApoC3 genetic variant.
What did differ? Those with beneficial ApoC3 mutations showed higher HDL cholesterol and lower triglyceride-to-HDL ratios—markers of efficient fat metabolism and robust metabolic health.
